REVEAL:
Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease

Martin Landray and Louise Bowman
on behalf of the HPS 3 / TIMI 55 - REVEAL Collaborative Group

Funded by MSD, British Heart Foundation, Medical Research Council
Designed, conducted and analysed independently of the funders
University of Oxford is the trial sponsor
HPS 3 / TIMI 55 - REVEAL Collaborative Group

Steering Committee

Principal Investigators: Martin Landray, Louise Bowman
Chair & Deputy Chair: Rory Collins, Eugene Braunwald
Trial Statistician: Jemma Hopewell

Regional representatives:

United Kingdom: Jane Armitage, Richard Haynes
N America: Christopher Cannon, Stephen Wiviott
Scandinavia: Terje Pedersen
China: Lixin Jiang
Italy: Aldo Maggioni

Other members:

Colin Baigent
Philip Barter
Yiping Chen
Zhengming Chen
Shinya Goto
Alastair Gray
Boby Mihaylova
Peter Sleight
Tamio Teramoto
Jonathan Tobert

Non-voting MSD representatives: Robert Blaustein, Paul DeLucca, Gerard van Leijenhorst, Yale Mitchel

Data Monitoring Committee

Peter Sandercock (Chair), David DeMets, Andrew Tonkin, John Kjekshus, James Neuberger, Jonathan Emberson (non-voting)

With many thanks to the more than 30,000 patients and hundreds of clinicians & researchers who made this trial possible.
Background

- Anacetrapib is a potent inhibitor of Cholesteryl Ester Transfer Protein (CETP) which doubles HDL-cholesterol and lowers LDL-cholesterol.

- Previous trials of other CETP inhibitors have been stopped after around 2 years of follow-up due to unexpected cardiovascular hazards (torcetrapib) or apparent lack of efficacy (dalcetrapib, evacetrapib).

- The REVEAL trial assessed the efficacy and safety of adding anacetrapib vs. placebo to effective doses of atorvastatin among patients with established occlusive vascular disease.
Effects of adding anacetrapib to intensive statin therapy

• Significant 9% proportional reduction in major coronary events (effect appears to be greater in later years of treatment)

• Small reduction in risk of new-onset diabetes mellitus

• No excess of symptomatic side-effects with anacetrapib (levels in adipose tissue rise with continued treatment)

• No excess of mortality, cancer or other serious adverse events (small increase in BP and small reduction in kidney function)

• Post-trial follow-up of all consenting participants (off-drug) to assess longer-term efficacy and safety of anacetrapib

Simultaneous publication in www.nejm.org
REVEAL trial design

Eligibility: 30,000 patients aged over 50 years with occlusive vascular disease

Background statin: Atorvastatin 20 or 80 mg daily (China: 10 or 20 mg)
⇒ Mean LDL-cholesterol 61 mg/dL (1.6 mmol/L)

Randomized: Anacetrapib 100 mg daily vs. matching placebo

Follow-up: ≥4 years and ≥1900 primary outcomes

Primary outcome: Major Coronary Event
(i.e. Coronary death, myocardial infarction, or coronary revascularization)

Primary outcome: Major coronary events
(Coronary death, myocardial infarction, or coronary revascularization)

- Placebo: 1803 (11.8%)
- Anacetrapib: 1640 (10.8%)

Rate ratio 0.91 (0.85 to 0.97)

P=0.004
Components of the primary outcome

<table>
<thead>
<tr>
<th>Type of Event</th>
<th>Anacetrapib (N=15225)</th>
<th>Placebo (N=15224)</th>
<th>Rate Ratio (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coronary death</td>
<td>388 (2.5)</td>
<td>420 (2.8)</td>
<td>0.92 (0.80–1.06)</td>
<td>0.25</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>669 (4.4)</td>
<td>769 (5.1)</td>
<td>0.87 (0.78–0.96)</td>
<td>0.007</td>
</tr>
<tr>
<td><strong>Coronary death or MI</strong></td>
<td>934 (6.1)</td>
<td>1048 (6.9)</td>
<td>0.89 (0.81–0.97)</td>
<td>0.008</td>
</tr>
<tr>
<td>Coronary revascularization</td>
<td>1081 (7.1)</td>
<td>1201 (7.9)</td>
<td>0.90 (0.83–0.97)</td>
<td>0.01</td>
</tr>
<tr>
<td><strong>Major coronary event</strong></td>
<td>1640 (10.8)</td>
<td>1803 (11.8)</td>
<td>0.91 (0.85–0.97)</td>
<td>0.004</td>
</tr>
</tbody>
</table>

No significant evidence of differential proportional effects among 23 pre-specified subgroup categories
Proportional reduction in Coronary death or MI vs. absolute reduction in non-HDL cholesterol (derived from published CTT meta-analysis)

- Statin vs. control >50 mg/dL reduction (4 trials)
- Statin vs. control <50 mg/dL reduction (17 trials)
- More vs. less 22 mg/dL reduction (5 trials)

REVEAL
## Other clinical assessments

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Anacetrapib</th>
<th>Placebo</th>
<th>Difference</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>New-onset diabetes mellitus</strong></td>
<td>510 (5.3%)</td>
<td>571 (6.0%)</td>
<td>-0.6%</td>
<td>0.05</td>
</tr>
<tr>
<td><strong>Blood pressure</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic (mmHg)</td>
<td>132.4</td>
<td>131.7</td>
<td>+0.7</td>
<td>0.002</td>
</tr>
<tr>
<td>Diastolic (mmHg)</td>
<td>77.6</td>
<td>77.4</td>
<td>+0.3</td>
<td>0.04</td>
</tr>
<tr>
<td>Hypertensive serious adverse events</td>
<td>151 (1.0%)</td>
<td>141 (0.9%)</td>
<td>+0.1%</td>
<td>0.56</td>
</tr>
<tr>
<td><strong>Kidney disease</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New-onset eGFR &lt;60 mL/min/1.73m²</td>
<td>1344 (11.5%)</td>
<td>1236 (10.6%)</td>
<td>+0.84%</td>
<td>0.04</td>
</tr>
<tr>
<td>Renal failure serious adverse events</td>
<td>169 (1.1%)</td>
<td>146 (1.0%)</td>
<td>+0.15%</td>
<td>0.20</td>
</tr>
</tbody>
</table>

No effect on vascular, non-vascular, or all-cause mortality

No effect on cancer, liver, muscle, cognitive function, or other adverse events
Effects of adding anacetrapib to intensive statin therapy

- Significant 9% proportional reduction in major coronary events (effect appears to be greater in later years of treatment)

- Small reduction in risk of new-onset diabetes mellitus

- No excess of symptomatic side-effects with anacetrapib (levels in adipose tissue rise with continued treatment)

- No excess of mortality, cancer or other serious adverse events (small increase in BP and small reduction in kidney function)

- Post-trial follow-up of all consenting participants (off-drug) to assess longer-term efficacy and safety of anacetrapib

Simultaneous publication in www.nejm.org